Page 2 - அங்கயலோசிங் ஸ்பான்டைலிடிஸ் நோய் நடவடிக்கை மதிப்பெண் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

There is considerable interest in the possibility of withdrawing treatment or lowering doses of biologic therapies for inflammatory and rheumatic diseases, for reasons including potential adverse effects with long-term use and the high cost of medications. Previous studies in which tumor necrosis factor (TNF) inhibitors were withdrawn found increased rates of flare, although in one study, reducing the dose frequency of certolizumab (Cimzia) was not associated with a greater likelihood of flare. Ixekizumab is a monoclonal antibody that targets interleukin (IL)-17A and has been approved for both radiographic and nonradiographic axial spondyloarthritis. Whether treatment withdrawal after remission could be achieved with IL-17 inhibition had not previously been investigated.

Ankylosing spondylitis disease activity scoreஅங்கயலோசிங் ஸ்பான்டைலிடிஸ் நோய் நடவடிக்கை மதிப்பெண்